Chronic Pain- Pipeline Insight, 2025

This “Chronic Pain- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Chronic Pain: Understanding

Chronic Pain: Overview

Pain starts in receptor nerve cells found beneath the skin and in organs throughout the body. When sick, injured, or have other type of problem, these receptor cells send messages along nerve pathways to the spinal cord, which then carries the message to the brain. Pain medicine reduces or blocks these messages before they reach the brain. Chronic pain is one of the most costly health problem in U.S. Increased medical expenses, lost income, lost productivity, compensation payments, and legal charges are some of the economic consequences of chronic pain. Consider the following Low back pain is one of the most significant health problems. Back pain is a common cause of activity limitation in adults. Cancer pain affects most people with advanced cancer.

There are many causes of chronic pain. It may have started from an illness or injury, from which may have long since recovered from, but pain remained. Or there may be an ongoing cause of pain, such as arthritis or cancer. Many people suffer chronic pain in the absence of any past injury or evidence of illness. Chronic pain can come in many different forms and appear across body. Common types of chronic pain include: Arthritis, or joint pain, Back pain, Neck pain, Cancer pain near a tumor, Headaches, including migraines, Testicular pain (orchialgia), Lasting pain in scar tissue.

The pathogenesis of pain sensation includes mechanisms that result in acute or chronic pain. Pain itself is described as an unpleasant sensory and emotional experience beginning with a peripheral stimulus that undergoes a physiological process ultimately resulting in the sensation of pain. Biologists recognize pain to be a common sign of potential tissue damage. Hence, pain sensation is protective in function. However, pathologic states of pain exist secondary to disruption of the nociceptive process both peripherally and centrally or secondary to psychological conditions. It is essential to identify these aberrant states of pain and distinguish them from situations of potential tissue damage. Chronic pain is defined as pain that exceeds 3 or 6 months duration.

The healthcare provider may physically examine body and order tests to look for the cause of the pain. They may have undergo the following tests Blood tests, Electromyography to test muscle activity, Imaging tests, such as X-rays and MRI, Nerve conduction studies to see if nerves are reacting properly, Reflex and balance tests, Spinal fluid tests, Urine tests.

Chronic pain affects all parts of life. The most effective treatment includes symptom relief and support. A multidisciplinary approach to pain management is often required to provide the needed interventions to help manage the pain. Pain management programs are usually done on an outpatient basis. Over-the-counter (OTC) medicines may include nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or acetaminophen. prescription pain medicines, including opioids, may be needed to provide stronger pain relief than aspirin. However, these drugs are reserved for more severe types of pain, as they have some potential for abuse and may have unpleasant and potentially very dangerous side effects.

"Chronic Pain- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pain pipeline landscape is provided which includes the disease overview and Chronic Pain treatment guidelines. The assessment part of the report embraces, in depth Chronic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Pain.

Chronic Pain Emerging Drugs Chapters

This segment of the Chronic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Pain Emerging Drugs

Adezunap (AP707): Apurano Pharmaceuticals GmbH

Adezunap is an Innovative nano-ecs-modulator being developed by Apurano Pharmaceuticals using patented PuranoTec® manufacturing process. The drug candidate is cannabinoid receptor CB1 agonists. With the use of active ingredient ADEZUNAP, the cannabis flower is processed using the patented PuranoTec® manufacturing process so that the cannabinoids (primarily ∆-9-THC) are available as an aqueous nanodispersion. The dispersion is applied sublingually as a mouth spray and the cannabinoids are absorbed quickly and effectively via the oral mucosa. This is possible because the lipophilic, water-insoluble cannabinoids are enclosed in a carrier that is surrounded by a water-soluble shell, the smart coating. Currently, the drug is in the Phase III stage of its development for the treatment of Chronic Pain.

• CNTX-6970: Centrexion Therapeutics

CNTX-6970 is a novel, potent and selective investigational CCR2 (C-C chemokine receptor type 2) antagonist currently in Phase 1 clinical trials. Chemokine receptor type 2, or CCR2, is the receptor for a cytokine known as monocyte chemoattractant protein-1, or MCP-1. Pre-clinical data suggest that CCR2, and MCP-1, are upregulated in immune cells, such as macrophages, microglial cells and astrocytes which play a central role in the origination of pain signals. CNTX-6970 has been shown to reduce pain signaling by inhibiting the CCR2 receptor which has a dual effect: stopping immune cells from releasing the potent cytokine MCP-1 and stopping MCP-1 from stimulating pain fibers to send pain signals. CNTX-6970 conferred analgesia in multiple pre-clinical chronic pain models, with particular activity in models of inflammatory pain. CNTX- 6970 is predicted to be well suited to treat inflammatory chronic pain, and Phase I studies have shown the treatment was well tolerated with demonstrated pharmacologic and pharmacodynamics activity. Currently, the drug is in the Phase II stage of its development for the treatment of Chronic Pain.

ITI-333: Intra-Cellular Therapies Inc

ITI333 is a novel compound that uniquely combines activity as an antagonist at serotonin 5-HT2A receptors and a partial agonist at μ-opioid receptors. These combined actions support the potential utility of ITI-333 in the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns. In addition, ITI-333 exhibits analgesic efficacy in acute and chronic preclinical models of pain supporting its potential utility in the management of pain. ITI333’s pharmacology is predominantly driven by high affinity binding to serotonin 5-HT2A (Ki = 8.3 nM) and μ-opioid (Ki = 11 nM) receptors. ITI333 shows modest affinity for dopamine D1 receptors, low affinity for κ-opioid receptors, and no binding to δ-opioid and NOP receptors. In vivo, ITI-333 elicits potent analgesia in rodents that is blocked by the opioid antagonist, naloxone. Further, ITI-333 mitigates symptoms associated with opioid withdrawal and blocks reinstatement of opioid mediated behaviors; behaviors thought to be associated with a return to opioid use after a period of abstinence. ITI-333 possesses low potential for abuse liability. Unlike opioid agonists, ITI-333 is not self-administered, does not develop physical tolerance/dependences and does not impair gastrointestinal and pulmonary function. This pharmacologic profile is unique and supports the study of ITI-333 in humans as a potential treatment for opioid use disorder and pain. Currently, the drug is in the Preclinical stage of its development for the treatment of Chronic Pain.

Chronic Pain: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Pain

There are approx. 20+ key companies which are developing the therapies for Chronic Pain. The companies which have their Chronic Pain drug candidates in the most advanced stage, i.e. Phase III include, Apurano Pharmaceuticals GmbH

Phases

The report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pain drugs.

Chronic Pain Report Insights

• Chronic Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Pain drugs?
• How many Chronic Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Apurano Pharmaceuticals
• Centrexion Therapeutics
• Neumentum Inc
• Grünenthal
• Synerkine Pharma
• Intra-Cellular Therapies Inc
• Mesoblast
• ANANDA Scientific Inc.

Key Products

• Adezunap (AP707)
• CNTX-6970
• NTM-006
• CNTX 0290
• (NOP)
• SK-01
• ITI-333
• Rexlemestrocel-L

This product will be delivered within 1-3 business days.